Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)’s recommenda... 由 Conrad, N, McInnes, IB, Mcmurray, JJV, Sattar, N

Clinical applications of machine learning algorithms: beyond the black box. 由 Watson, DS, Krutzinna, J, Bruce, IN, Griffiths, CE, McInnes, IB, Barnes, MR, Floridi, L

Gout and incidence of 12 cardiovascular diseases: a case–control study including 152 663 individuals with gout and 709 981 matched controls 由 Ferguson, LD, Molenberghs, G, Verbeke, G, Rahimi, K, Rao, S, McInnes, IB, McMurray, JJV, Sattar, N, Conrad, N

Baricitinib, tofacitinib, upadacitinib, filgotinib, and cytokine signaling in human leukocyte subpopulations: an updated ex-vivo comparison 由 McInnes, IB, Rocha, G, Higgs, R, Dairaghi, D, Wehrman, T, Wang, E, Zhang, X, Terres, JR, Rooney, T, Taylor, PC

Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research 由 Pollock, J, Raza, K, Pratt, AG, Hanson, H, Siebert, S, Filer, A, Isaacs, JD, Buckley, CD, McInnes, IB, Falahee, M

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase... 由 Coates, LC, Rahman, P, Mease, PJ, Shawi, M, Rampakakis, E, Kollmeier, AP, Xu, XL, Chakravarty, SD, McInnes, IB, Tam, L-S

Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis 由 Akbar, M, MacDonald, L, Crowe, LAN, Carlberg, K, Kurowska-Stolarska, M, Ståhl, PL, Snelling, SJB, McInnes, IB, Millar, NL

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phas... 由 Coates, L, Gossec, L, Theander, E, Bergmans, P, Neuhold, M, Karyekar, CS, Shawi, M, Noel, W, Schett, G, McInnes, IB

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients 由 Orbai, A-M, McInnes, IB, Coates, LC, Husni, ME, Gladman, DD, Gossec, L, Pricop, L, Chambenoit, O, Meng, X, Mease, PJ

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis 由 Pournara, E, Kormaksson, M, Nash, P, Ritchlin, CT, Kirkham, BW, Ligozio, G, Pricop, L, Ogdie, A, Coates, LC, Schett, G, McInnes, IB

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy 由 Krueger, JG, Eyerich, K, Kuchroo, VK, Ritchlin, CT, Abreu, MT, Elloso, MM, Fourie, A, Fakharzadeh, S, Sherlock, JP, Yang, Y, Cua, DJ, McInnes, IB

Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in t... 由 Conrad, N, Misra, S, Verbakel, JY, Verbeke, G, Molenberghs, G, Taylor, PN, Mason, J, Sattar, N, McMurray, JJV, McInnes, IB, Khunti, K, Cambridge, G

The impact of the presence of autoantibodies against citrullinated, carbamylated and acetylated peptides on radiographic progression in patients with new onset rheumatoid arthritis... 由 Nijjar, JS, Morton, FR, Bang, H, van der Heijde, D, Gilmour, A, Paterson, C, McInnes, IB, Raza, K, Buckley, C, Scottish Early Rheumatoid Arthritis Inception Cohort Investigators

Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis 由 Rahman, P, Boehncke, W-H, Mease, PJ, Gottlieb, AB, McInnes, IB, Shawi, M, Wang, Y, Sheng, S, Kollmeier, AP, Theander, E, Yu, J, Leibowitz, E, Marrache, AM, Coates, LC

Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies 由 Mease, PJ, Merola, JF, Tanaka, Y, Gossec, L, McInnes, IB, Ritchlin, CT, Landewé, RBM, Asahina, A, Ink, B, Heinrichs, A, Bajracharya, R, Shende, V, Coarse, J, Coates, LC

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active... 由 Ritchlin, CT, Coates, LC, McInnes, IB, Mease, PJ, Merola, JF, Tanaka, Y, Asahina, A, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Landewé, R

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies 由 Taylor, PC, Kremer, J, Emery, P, Zuckerman, S, Ruotolo, G, Zhong, J, Chen, L, Witt, S, Saifan, C, Kurzawa, M, Otvos, JD, Connelly, MA, Macias, W, Schlichting, DE, Rooney, T, de Bono, S, McInnes, IB

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) 由 McInnes, IB, Asahina, A, Coates, LC, Landewé, R, Merola, JF, Ritchlin, CT, Tanaka, Y, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Mease, PJ

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III... 由 Coates, LC, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gosse, L, Orbai, A-M, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Merola, JF

Bimekizumab in patients with active psoriatic arthritis and prior inadequate response or intolerance to tumour necrosis factor inhibitors: a randomised, double-blind, placebo-contr... 由 Merola, JF, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gossec, L, Gottlieb, AB, Thaçi, D, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Coates, LC